A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia

Indian Journal of Urology

Volumn 25, Issue 4, 2009, Pages 474-478

  Agrawal, Madhu S ^a   Yadav, Abhishek ^a   Yadav, Himanshu ^a   Singh, Amit K ^a   Lavania, Prashant ^a   Jaiman, Richa ^a  

^a S N MEDICAL COLLEGE   (India)

Author keywords

Acute urinary retention; Alfuzosin; BPH; Tamsulosin; Trial without catheter

Indexed keywords

ALFUZOSIN; PLACEBO; TAMSULOSIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CATHETERIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; URINE FLOW RATE; URINE RETENTION;

EID: 72749125827     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.57917     Document Type: Article

References (22)

1. Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007;28:770-779
2. Emberton M, Fitzpatrick JM. The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int 2008;101:27-32.
3. Altarac S. Alpha-adrenergic blockers as a support in the treatment of acute urinary retention. Lijec Vjesn 2006;128:233-237
4. McNeill SA. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 2004;45:325-332
5. Kuritzky L. Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. Compr Ther 2005;31:194-208.
6. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int 2006;97:12-15
7. Fitzpatrick JM, Kirby RS. Management of acute urinary retention. BJU Int 2006;97:16-20.
8. Hartung R. Do alpha-blockers prevent the occurrence of acute urinary retention? Eur urol 2001;39:13-18
9. Oelke M, Höfner K, Berges RR, Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results. Urologe A. 2002;41:425-441
10. Nickel JC. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia. Urology 2003;62:34-41.
11. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 2005;95:29-36.
12. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005;95:1006-1012
13. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002;19:135-161
14. Höfner K, Jonas U. Alfuzosin: a clinically uroselective alpha1-blocker. World J Urol 2002;19:405-412
15. McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. BJU Int 1999;84:622-627
16. Gopi SS, Goodman CM, Robertson A, Byrne DJ. A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol. Scientific World Journal 2006;6:2436-2441
17. McNeill SA, Hargreave TB, Roehrborn CG. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 2005;65:83-89
18. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005;95:354-357
19. Hua LX, Wu HF, Sui YG, Chen SG, Xu ZQ, Zhang W, et al. Tamsulosin in the treatment of benign prostatic hyperplasia patients with acute urinary retention. Zhonghua Nan Ke Xue 2003;9:510-511
20. Guay DR. Extended-release alfuzosin hydrochloride: a new alphaadrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother 2004;2:14-23.
21. Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 2008;101:847-852
22. Seftel AD, Rosen RC, Rosenberg MT, Sadovsky R. Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: practice patterns according to physician specialty. Int J Clin Pract 2008;62:614-622